Heparin monitoring study at Vanderbilt
Part of Heart & circulation clinical trials.
This study looks at how well a blood test (PTT) monitors the blood thinner heparin in hospital patients. If you are getting heparin through an IV, this research may help improve how your treatment is managed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are a patient at Vanderbilt University Hospital (either observation or inpatient)
- You are receiving the blood thinner heparin through an IV, and it is being monitored with the PTT nurse-managed protocol
- Your baseline PTT test result is between 0 and 36.0 seconds
- Your baseline heparin level (anti-Xa assay) is between 0 and 0.3
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a blood test measuring a substance called anti-factor Xa activity can help predict dangerous blood clots in critically ill patients. If you join, researchers will follow you to see if the test results can prevent clots.
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
This study looks at whether genetic and blood test information can help manage heparin-induced thrombocytopenia (HIT), a condition where blood platelets drop after heparin use. If you’ve been evaluated for HIT and received certain heparin medicines, your results may help researchers choose safer, more personalized care.
This study compares two ways of measuring how well the blood thinner heparin works in children after heart surgery in the ICU. The goal is to find the best method to keep the dose safe and effective.
This study tests a blood-derived medicine (antithrombin) to help people who do not respond well to the blood thinner heparin during heart surgery. It aims to make surgery safer by improving blood thinning.
This study tests whether a blood thinner (LMWH) can help prevent dangerous blood clots in teens with a central line and infection or inflammation in the pediatric intensive care unit (PICU). It aims to find a safer, more personalized way to use preventive treatment.
Hear when a new Blood Clot trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.